肝癌治療藥物市場規模、佔有率、成長分析，按藥物、類型、分銷管道、地區分類 - 按行業預測，2024-2031

2022年全球肝癌藥物市場規模為29.8億美元，從2023年的35.1億美元成長到2031年的131.2億美元，預計在預測期間（2024年-2031年）將以年複合成長率為 17.9%。

肝癌治療領域的市場成長是由新藥供應量的增加、產品線的強大和公眾意識的提高所推動的。肝癌發生率的上升進一步推動了這種成長，尤其是在生活方式不健康的老年人中。肝細胞癌（HCC）佔原發性肝癌的 75-90%。許多危險因素，例如肝炎感染和肝硬化，都是可以改變的，這為改變生活方式和接種肝炎疫苗等預防策略提供了機會。從地理來看，北美和南歐的肝癌死亡率最高，而東亞的男性（每10萬人中有31.9人）和女性（每10萬人中有10.2人）發病率最高。這凸顯了需要有針對性的介入和治療的重要領域。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特分析與影響
  • 競爭公司之間的敵對關係
  • 替代品的威脅
  • 買方議價能力
  • 新進入者的威脅
  • 供應商的議價能力

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術進步
• 監管環境
• 案例研究

肝癌治療藥物市場規模：依藥物分類

• 市場概況
• 標靶治療
• 免疫療法
• 化療

肝癌治療藥物市場規模：依類型

• 市場概況
• 肝細胞癌
• 膽管癌
• 肝母細胞瘤
• 其他

肝癌治療藥物市場規模：依通路分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

肝癌治療藥物市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Exelixis, Inc.
• Merck KGaA
• Bristol-Myers Squibb Company
• Bayer AG
• Thermo Fisher Scientific Inc.
• Pfizer Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Abbott Laboratories
• Gilead Sciences
• Zydus Pharmaceuticals Inc
• AbbVie Inc.
• Johnson & Johnson Services Inc.

結論和建議

Global Liver Cancer Drugs Market size was valued at USD 2.98 billion in 2022 and is poised to grow from USD 3.51 billion in 2023 to USD 13.12 billion by 2031, growing at a CAGR of 17.9% during the forecast period (2024-2031).

Market growth in the liver cancer treatment sector is driven by increased availability of novel drugs, robust pipelines, and heightened public awareness. The rising incidence of liver cancer, particularly among the aging population with unhealthful lifestyles, is further propelling this growth. Hepatocellular carcinomas (HCCs) represent 75-90% of primary liver cancer cases. Many risk factors, such as hepatitis infection and cirrhosis, are modifiable, presenting opportunities for preventive strategies like lifestyle changes and hepatitis vaccination. Geographically, North America and Southern Europe experience the highest mortality rates for liver cancer, while Eastern Asia shows the most significant incidence rates for males (31.9 per 100,000) and females (10.2 per 100,000). This highlights critical areas for targeted interventions and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cancer Drugs Market Segmental Analysis

Global Liver Cancer Drugs Market is segmented by Drug, Type, Distribution Chanel, and region. Based on Drug, the market is segmented into Targeted Therapy, Immunotherapy, and Chemotherapy. Based on Type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and Others. Based on Distribution Chanel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cancer Drugs Market

The global market for liver cancer drugs is driven by the alarming rise in liver cancer cases, which sees around one million new diagnoses annually worldwide. The increasing number of smokers and alcohol consumers, alongside urbanization, significantly contributes to liver-related health issues. Government initiatives and investments from global healthcare organizations further bolster the growth of this market. Moreover, the emergence of innovative liver cancer medications and a rise in FDA approvals specifically targeting hepatocellular carcinoma-which represents nearly 90% of liver cancer cases-reflects heightened research and development efforts to combat this critical disease, indicating a promising future for the industry.

Restraints in the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market faces significant constraints that could impede its growth trajectory. Key among these are stringent regulatory requirements imposed by governments, which may hamper the approval process for numerous small molecules and biologics in developed nations. As a result, products that are not equipped with cutting-edge technology may encounter elevated rates of processing errors, compromised quality, and heightened cost challenges. These factors collectively pose obstacles for market expansion, potentially leading to reduced access and limited options for patients and healthcare providers. Consequently, the overall potential for growth within this therapeutic market may be significantly affected.

Market Trends of the Global Liver Cancer Drugs Market

The Global Liver Cancer Drugs market is experiencing a significant upward trend, largely driven by robust research and development initiatives aimed at enhancing treatment outcomes. With an emphasis on prolonging patient survival and improving quality of life, pharmaceutical companies are increasingly focusing on innovative approaches such as immunotherapy and targeted therapies. Collaborative efforts, exemplified by partnerships like that between Sirnaomics and Innovent Biologics for clinical research on Tyvy and STP705, are accelerating advancements in liver cancer treatment. This strategic alliance and others like it are not only propelling clinical progress but also expanding the market's potential, thereby positioning the sector for sustained growth and investment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Liver Cancer Drugs Market Size by Drug & CAGR (2024-2031)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Chemotherapy

Global Liver Cancer Drugs Market Size by Type & CAGR (2024-2031)

• Market Overview
• Hepatocellular Carcinoma
• Cholangio Carcinoma
• Hepatoblastoma
• Others

Global Liver Cancer Drugs Market Size by Distribution Chanel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Liver Cancer Drugs Market Size & CAGR (2024-2031)

• North America (Drug, Type, Distribution Chanel)
  • US
  • Canada
• Europe (Drug, Type, Distribution Chanel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug, Type, Distribution Chanel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Drug, Type, Distribution Chanel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug, Type, Distribution Chanel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation